Fukuchi M, Kido A, Hyodo K, Tachibana K, Onoue K, Morita T, Nagai K
J Nucl Med. 1979 Aug;20(8):827-32.
We have investigated the thyroid uptake of Tl-201 in 37 patients with various types of goiter, and in six with normal thyroids. Significant thallium uptake was found in all cases in which there was thyroid enlargement, including Graves' disease, toxic thyroid nodule, primary hypothyroidism, simple goiter, Hashimoto's disease, thyroid carcinoma, and thyroid adenoma. If goiter was absent, however, there was no demonstrable uptake--e.g., in secondary hypothyroidism, subacute thyroiditis, and the normal controls. Thallium uptake did not correlate with thyroid function tests such as BMR, T3-RU, T3, T4, TSH, antithyroid antibodies, or the 24-hr I-131 uptake. In 23 patients with diffuse goiter, on the other hand, maximum Tl-201 uptake correlated well with thyroid weight: r = 0.836 (p less than 0.001); y = 0.02 x + 0.06.
我们对37例患有各种类型甲状腺肿的患者以及6例甲状腺正常的患者进行了铊-201甲状腺摄取情况的研究。在所有甲状腺肿大的病例中均发现有明显的铊摄取，包括格雷夫斯病、毒性甲状腺结节、原发性甲状腺功能减退症、单纯性甲状腺肿、桥本氏病、甲状腺癌和甲状腺腺瘤。然而，如果没有甲状腺肿大，例如在继发性甲状腺功能减退症、亚急性甲状腺炎以及正常对照中，则未发现有可证实的摄取。铊摄取与甲状腺功能检查如基础代谢率（BMR）、三碘甲状腺原氨酸摄取率（T3-RU）、T3、T4、促甲状腺激素（TSH）、抗甲状腺抗体或24小时碘-131摄取均无相关性。另一方面，在23例弥漫性甲状腺肿患者中，铊-201最大摄取量与甲状腺重量密切相关：r = 0.836（p＜0.001）；y = 0.02x + 0.06。
